Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557

Watchlist Manager
Jiangsu Kanion Pharmaceutical Co Ltd Logo
Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557
Watchlist
Price: 14.1 CNY -0.21% Market Closed
Market Cap: 8.2B CNY
Have any thoughts about
Jiangsu Kanion Pharmaceutical Co Ltd?
Write Note

Jiangsu Kanion Pharmaceutical Co Ltd
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jiangsu Kanion Pharmaceutical Co Ltd
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557
Other Receivables
ÂĄ352.1m
CAGR 3-Years
-8%
CAGR 5-Years
-16%
CAGR 10-Years
-4%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Receivables
ÂĄ111m
CAGR 3-Years
-38%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Receivables
ÂĄ297.6m
CAGR 3-Years
19%
CAGR 5-Years
8%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Receivables
ÂĄ1.3B
CAGR 3-Years
-23%
CAGR 5-Years
3%
CAGR 10-Years
0%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Receivables
ÂĄ3.1B
CAGR 3-Years
33%
CAGR 5-Years
-10%
CAGR 10-Years
-2%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Receivables
ÂĄ74.5m
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jiangsu Kanion Pharmaceutical Co Ltd
Glance View

Market Cap
8.2B CNY
Industry
Pharmaceuticals

In the bustling landscape of the Chinese pharmaceutical industry, Jiangsu Kanion Pharmaceutical Co Ltd emerges as a pivotal player, seamlessly blending centuries-old traditional Chinese medicine (TCM) with cutting-edge modern technology. Founded in 1975, the company has carved a niche for itself by focusing on the research, development, and production of both TCM and integrated Western medicine. Kanion is renowned for its innovative approach, transforming ancient herbal remedies into scientifically-backed therapeutic solutions. The company's approach is not just about preserving tradition but rather enhancing it, ensuring that products meet rigorous modern medical standards, thereby appealing to a broad spectrum of healthcare needs. Kanion generates revenue through a diversified portfolio spanning herbal medicines, biochemical drugs, and health supplements. By implementing modern R&D methodologies, the company supports its vast array of products with robust clinical research, catering to both domestic and international markets. One of their key revenue streams is prescription medicines sold in hospitals and clinics, complemented by over-the-counter products available in pharmacies. Additionally, Kanion's investment in strategic partnerships and technological advancements has opened pathways for export, further amplifying its financial success. Through this blend of tradition and innovation, Jiangsu Kanion Pharmaceutical Co Ltd has established a resilient business model that thrives on the growing global acceptance of combining Eastern and Western medicinal practices.

Intrinsic Value
23.97 CNY
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Jiangsu Kanion Pharmaceutical Co Ltd's Other Receivables?
Other Receivables
352.1m CNY

Based on the financial report for Sep 30, 2024, Jiangsu Kanion Pharmaceutical Co Ltd's Other Receivables amounts to 352.1m CNY.

What is Jiangsu Kanion Pharmaceutical Co Ltd's Other Receivables growth rate?
Other Receivables CAGR 10Y
-4%

Over the last year, the Other Receivables growth was 11%. The average annual Other Receivables growth rates for Jiangsu Kanion Pharmaceutical Co Ltd have been -8% over the past three years , -16% over the past five years , and -4% over the past ten years .

Back to Top